CN105394775A - 一种纳米肽化活性钙 - Google Patents
一种纳米肽化活性钙 Download PDFInfo
- Publication number
- CN105394775A CN105394775A CN201510751749.4A CN201510751749A CN105394775A CN 105394775 A CN105394775 A CN 105394775A CN 201510751749 A CN201510751749 A CN 201510751749A CN 105394775 A CN105394775 A CN 105394775A
- Authority
- CN
- China
- Prior art keywords
- peptide
- calcium
- nano
- mass ratio
- calcium activated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 75
- 239000011575 calcium Substances 0.000 title claims abstract description 74
- 229910052791 calcium Inorganic materials 0.000 title claims abstract description 73
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 title claims abstract description 71
- 238000001338 self-assembly Methods 0.000 claims abstract description 14
- 239000002105 nanoparticle Substances 0.000 claims abstract description 13
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims abstract description 9
- 238000000034 method Methods 0.000 claims abstract description 7
- 239000001110 calcium chloride Substances 0.000 claims abstract description 6
- 229910001628 calcium chloride Inorganic materials 0.000 claims abstract description 6
- 230000008569 process Effects 0.000 claims abstract description 6
- 238000000502 dialysis Methods 0.000 claims abstract description 4
- 238000004806 packaging method and process Methods 0.000 claims abstract description 3
- 230000035484 reaction time Effects 0.000 claims description 10
- 238000006243 chemical reaction Methods 0.000 claims description 9
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims description 4
- 229910001424 calcium ion Inorganic materials 0.000 claims description 4
- 238000004108 freeze drying Methods 0.000 claims description 4
- 229920001661 Chitosan Polymers 0.000 claims description 3
- 241000370738 Chlorion Species 0.000 claims description 3
- 235000009508 confectionery Nutrition 0.000 claims description 3
- 230000006196 deacetylation Effects 0.000 claims description 3
- 238000003381 deacetylation reaction Methods 0.000 claims description 3
- 239000003223 protective agent Substances 0.000 claims description 3
- 230000006798 recombination Effects 0.000 claims description 3
- 238000005215 recombination Methods 0.000 claims description 3
- 239000002131 composite material Substances 0.000 claims description 2
- 238000005507 spraying Methods 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 238000002360 preparation method Methods 0.000 abstract description 8
- 238000010521 absorption reaction Methods 0.000 abstract description 5
- 238000005516 engineering process Methods 0.000 abstract description 4
- 239000002245 particle Substances 0.000 abstract description 4
- 235000013305 food Nutrition 0.000 abstract description 3
- 229930003316 Vitamin D Natural products 0.000 abstract description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 abstract description 2
- 235000019166 vitamin D Nutrition 0.000 abstract description 2
- 239000011710 vitamin D Substances 0.000 abstract description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 abstract description 2
- 229940046008 vitamin d Drugs 0.000 abstract description 2
- 229940069978 calcium supplement Drugs 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 238000001035 drying Methods 0.000 abstract 1
- 239000002994 raw material Substances 0.000 abstract 1
- 239000013589 supplement Substances 0.000 abstract 1
- 229960005069 calcium Drugs 0.000 description 58
- 150000001413 amino acids Chemical group 0.000 description 5
- 230000001502 supplementing effect Effects 0.000 description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical group [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 206010006956 Calcium deficiency Diseases 0.000 description 3
- 102000057297 Pepsin A Human genes 0.000 description 3
- 108090000284 Pepsin A Proteins 0.000 description 3
- 229940111202 pepsin Drugs 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 2
- 239000001527 calcium lactate Substances 0.000 description 2
- 229960002401 calcium lactate Drugs 0.000 description 2
- 235000011086 calcium lactate Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 210000000110 microvilli Anatomy 0.000 description 2
- 241001466460 Alveolata Species 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229960003563 calcium carbonate Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Inorganic Chemistry (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明涉及一种纳米肽化活性钙，属于食品深加工技术领域，其特征是以氯化钙为原料，经肽化处理、透析、纳米粒自组装、干燥、包装工序，制得稳定性好、吸收率高的肽化活性钙补充制剂；该工艺不需要昂贵复杂的设备，生产成本低，易于实现产业化生产，是一种绿色加工技术；本发明生产的纳米肽化活性钙，粒径均匀，稳定性好，吸收率高，吸收不依赖维生素D的摄入，并可实现肽与钙的双效同补，是一种极具市场推广前景的肽化活性钙补充制剂。
Description
技术领域
本发明属于食品深加工技术领域，具体涉及一种纳米肽化活性钙产品。
背景技术
钙是人体必需的矿物质元素之一，在骨骼组成、肌肉收缩、细胞吞噬及酶的激活等多种生命活动中具有重要作用。人体中的钙主要来自食物，由于钙的吸收利用率较低，缺钙已成为全球性的营养问题之一。我国最近一次全国膳食调查显示，膳食中钙的摄入量不到每日供给需要量800mg的一半(49.2％)，城市稍高(53.3％)，农村较低(47.1％)，儿童、孕妇、老人缺钙更为明显。在我国由缺钙造成的骨质疏松病例较30年前增加了3倍，60岁以上老人发病率达59％。因此，为保证人体健康和增强体质，科学合理地补钙并促进人体对钙的吸收至关重要。
目前市售的第一代、第二代补钙产品，其有效成分多为碳酸钙、乳酸钙或葡萄糖酸钙。碳酸钙不溶于水，进入胃以后必须由胃酸中和并解离成Ca2+才可吸收，对胃有强烈刺激性，生物利用率仅为30％-40％左右。乳酸钙、葡萄糖酸钙溶解性较好，但含钙量低，仅为13.0％和9.0％，吸收利用率30％-40％左右，且葡萄糖酸钙不适合糖尿病人群。第三代补钙产品为氨基酸螯合钙，生物利用率大大提高，达60％-80％左右，但其吸收利用受氨基酸转运载体的制约。
发明内容
本发明的目的是提供一种纳米肽化活性钙制品，从而提供一种稳定性好、钙吸收率高的肽化活性钙补充制剂，以弥补已有钙制剂的不足。
一种纳米肽化活性钙，其特征在于所述的纳米肽化活性钙是以如下步骤进行制备：
1)肽化处理：用质量比为5％的氯化钙溶液与质量比为10％的肽溶液进行复合反应，形成肽化活性钙溶液；
肽化条件为：肽的氨基酸序列结构为DGDDGEAG(从N端到C端，-Asp-Gly-Asp-Asp-Gly-Glu-Ala-Gly-)；这种活性肽富含谷氨酸及天冬氨酸，肽与氯化钙的质量比为3-5：1、反应温度37-50℃、反应时间30-60min；
2)透析：采用透析处理去除步骤1)中的经肽化处理后的游离的钙离子和氯离子；
3)纳米粒自组装：对经过步骤2)中的肽化活性钙溶液与质量比为1-3％的壳聚糖溶液进行自组装，形成壳聚糖-肽-钙复合物纳米粒；
自组装条件为：壳聚糖与肽化活性钙的质量比为1：1-3、温度37-50℃、反应时间30-60min；
4)干燥：对经过步骤3)中纳米粒自组装后的溶液进行冷冻干燥或喷雾干燥，且在干燥前添加质量比为5％的甘露醇保护剂；
5)包装：干燥好的肽化活性钙经包装后即为纳米肽化活性钙制品。
优选的，肽化条件为肽与氯化钙的质量比为5：1、反应温度50℃、反应时间30min，自组装条件为：壳聚糖与肽化活性钙的质量比为1：1、温度50℃、反应时间30min；
优选的，本发明采用的壳聚糖的分子量大小在5-10万道尔顿之间，脱乙酰度大于90％以上，在一定的条件下，自组装成的纳米粒粒径小于600nm。
该发明的纳米肽化活性钙制备工艺简单，易于产业化，反应条件温和，是一种绿色加工技术。肽化活性钙与自然界中唯一存在的碱性阳离子多糖壳聚糖进行自组装，形成稳定的纳米粒，克服了肽化活性钙在胃肠道内吸收存在胃蛋白酶酶解、胃酸降解、肠肽酶酶解及小肠上皮细胞穿透等多重障碍，提高了肽化活性钙的生物利用率。经研究发现，本发明所得的肽化活性钙具有比氨基酸螯合钙更易吸收的特性，且运转不需要氨基酸载体、不易饱和，不引起高血钙症，对胃蛋白酶及小肠刷状缘膜酶的稳定性好，转运吸收率高，并可实现肽与钙的双效同补，是一种极具推广前景的肽化活性钙补充制剂。
附图说明
图1：本发明的纳米肽化活性钙的扫描电镜图。
图2：本发明的纳米肽化活性钙的透射电镜图。
具体实施方式
以下结合具体实施方式来进一步说明本发明。
实施例1：一种纳米肽化活性钙，具体制备步骤如下：
1)肽化处理：
质量比为5％的氯化钙溶液与10％肽溶液进行复合反应，形成肽化活性钙溶液；肽与氯化钙的质量比为5：1、反应温度50℃、反应时间30min，制备肽化活性钙；
2)透析：将肽化活性钙溶液置于的分子截留量为500道尔顿的透析袋中，去除游离钙离子和氯离子；
3)纳米粒自组装：将经过透析的肽化活性钙溶液与质量比2％的壳聚糖溶进行纳米粒自组装，壳聚糖与肽化活性钙的质量比为1：1、温度50℃、反应时间30min；
4)干燥：在纳米粒体系中添加5％的甘露醇保护剂后进行冷冻干燥；
5)包装：干燥好的肽化活性钙经避光、防潮包装后，得到纳米肽化活性钙制品。
上述肽为-Asp-Gly-Asp-Asp-Gly-Glu-Ala-Gly-肽，上述壳聚糖的分子量为10万道尔顿，脱乙酰度为90％。
本发明制备的纳米肽化活性钙，扫描电镜图显示钙离子均匀结合在肽的表面，呈规整的蜂窝状结构(图1)；纳米粒粒径均匀，平均粒径小于200nm，(图2)，稳定性好，吸收率高。纳米肽化活性钙溶液在室温条件下贮藏2个月，其粒径未发生明显变化；纳米肽化活性钙溶液冷冻干燥后再复溶，其产品粒径未发生显著变化；纳米肽化活性钙经胃蛋白酶及小肠刷状缘膜酶消化后，其钙结合率仍保持在80％以上；相对于无机钙，纳米肽化活性钙在细胞水平的钙吸收率和钙保留率分别提高了9.8％和96.5％。
本发明的纳米肽化活性钙吸收率高、稳定性好，吸收不依赖维生素D的摄入，并可实现肽与钙的双效同补，是一种具有很好市场推广前景的肽、钙双效补充制剂。
Claims (3)
1.一种纳米肽化活性钙，其特征在于所述的纳米肽化活性钙是以如下步骤进行制备：
1)肽化处理：用质量比为5％的氯化钙溶液与质量比为10％的肽溶液进行复合反应，形成肽化活性钙溶液；
肽化条件为：肽的氨基酸序列结构为DGDDGEAG，从N端到C端其氨基酸序列为Asp-Gly-Asp-Asp-Gly-Glu-Ala-Gly；肽与氯化钙的质量比为3-5：1、反应温度37-50℃、反应时间30-60min；
2)透析：采用透析处理去除步骤1)中的经肽化处理后的游离的钙离子和氯离子；
3)纳米粒自组装：对经过步骤2)中的肽化活性钙溶液与质量比为1-3％的壳聚糖溶液进行自组装，形成壳聚糖-肽-钙复合物纳米粒；
自组装条件为：壳聚糖与肽化活性钙的质量比为1：1-3、温度37-50℃、反应时间30-60min；
4)干燥：对经过步骤3)中纳米粒自组装后的溶液进行冷冻干燥或喷雾干燥，且在干燥前添加质量比为5％的甘露醇保护剂。
5)包装：干燥好的肽化活性钙经包装后即为纳米肽化活性钙制品。
2.如权利要求1所述的纳米肽化活性钙，其特征在于，肽化条件为肽与氯化钙的质量比为5：1、反应温度50℃、反应时间30min，自组装条件为：壳聚糖与肽化活性钙的质量比为1：1、温度50℃、反应时间30min。
3.如权利要求1所述的纳米肽化活性钙，其特征在于，所述的壳聚糖分子量为5-10万道尔顿，脱乙酰度90％以上。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510751749.4A CN105394775B (zh) | 2015-11-07 | 2015-11-07 | 一种纳米肽化活性钙 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510751749.4A CN105394775B (zh) | 2015-11-07 | 2015-11-07 | 一种纳米肽化活性钙 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105394775A true CN105394775A (zh) | 2016-03-16 |
| CN105394775B CN105394775B (zh) | 2018-06-08 |
Family
ID=55460821
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510751749.4A Active CN105394775B (zh) | 2015-11-07 | 2015-11-07 | 一种纳米肽化活性钙 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105394775B (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110483620A (zh) * | 2019-09-19 | 2019-11-22 | 大连工业大学 | 一种海参卵源八肽及其钙纳米复合物的制备方法与应用 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1944457A (zh) * | 2006-07-14 | 2007-04-11 | 中国科学院南海海洋研究所 | 一种谷胱甘肽螯合钙及其制备方法,用途和组合物 |
| CN102241733A (zh) * | 2011-05-18 | 2011-11-16 | 吉林大学 | 鹿骨胶原多肽螯合钙及肠溶胶囊和制备方法 |
| CN102423298A (zh) * | 2011-11-18 | 2012-04-25 | 国家海洋局第三海洋研究所 | 一种核壳结构胶原多肽螯合钙纳米粒子的制备方法 |
| CN103230020A (zh) * | 2013-04-15 | 2013-08-07 | 武汉工业学院 | 一种蛋白质短肽螯合钙的制备方法 |
-
2015
- 2015-11-07 CN CN201510751749.4A patent/CN105394775B/zh active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1944457A (zh) * | 2006-07-14 | 2007-04-11 | 中国科学院南海海洋研究所 | 一种谷胱甘肽螯合钙及其制备方法,用途和组合物 |
| CN102241733A (zh) * | 2011-05-18 | 2011-11-16 | 吉林大学 | 鹿骨胶原多肽螯合钙及肠溶胶囊和制备方法 |
| CN102423298A (zh) * | 2011-11-18 | 2012-04-25 | 国家海洋局第三海洋研究所 | 一种核壳结构胶原多肽螯合钙纳米粒子的制备方法 |
| CN103230020A (zh) * | 2013-04-15 | 2013-08-07 | 武汉工业学院 | 一种蛋白质短肽螯合钙的制备方法 |
Non-Patent Citations (2)
| Title |
|---|
| DA CHEN，ETAL: "Isolation of a calcium-binding peptide from tilapia scale protein hydrolysate and its calcium bioavailability in rats", 《JOURNAL OF FUNCTIONAL FOODS》 * |
| 朱婉萍等: "《甲壳素及其衍生物的研究与应用》", 30 November 2014, 浙江大学出版社 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110483620A (zh) * | 2019-09-19 | 2019-11-22 | 大连工业大学 | 一种海参卵源八肽及其钙纳米复合物的制备方法与应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105394775B (zh) | 2018-06-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101007865B1 (ko) | 키토산 및 피틴산을 포함하는 서방성 키토산 캡슐 | |
| CN1340079A (zh) | 含有副淀粉的冷冻干燥试剂、它的制备和用途 | |
| CN101061867A (zh) | γ－聚谷氨酸(γ－PGA,H形式)及γ－聚谷氨酸盐用于膳食产品中作为营养助剂 | |
| CN101829143A (zh) | 含有硅酸的挤出物的制备方法、所述的挤出物、其应用和含有所述挤出物的药物组合物 | |
| CN110679953A (zh) | 一种包埋蛋清源活性肽的纳米脂质体的制备方法 | |
| CN102823885A (zh) | 一种海参咀嚼片及其制备方法 | |
| CN102362853A (zh) | 一种京尼平交联大豆蛋白基茶碱控释凝胶制剂及其制备方法 | |
| CN105394775A (zh) | 一种纳米肽化活性钙 | |
| JP2007524690A (ja) | 活性物質の生体内利用効率を高めるためのガラクトマンナン及び／又はグルコマンナン | |
| CN104490933B (zh) | 鳄鱼血纳米微胶囊及其制备方法 | |
| CN105494843A (zh) | 一种蓝莓压片糖果制备方法 | |
| KR20210012979A (ko) | 레반-단백질 나노복합체 및 이의 용도 | |
| Prasanthi et al. | A brief review on chitosan and application in biomedical field | |
| CN105616323A (zh) | 一种滋养护肤的蚕丝海绵制品及其制备方法 | |
| CN101935607A (zh) | 海参保健酒及其制备方法 | |
| JP5805522B2 (ja) | 粉粒状複合体及び創傷被覆材 | |
| CN106853243A (zh) | 改善骨质疏松和增加骨密度的海洋肽化活性钙及制备工艺 | |
| CN109219358A (zh) | 用于降低有害/毒性物质的消化率或吸收率的食用组合物 | |
| CN102783550A (zh) | 酪蛋白复合多肽啤特果果脯制备工艺及其产品 | |
| CN104287032B (zh) | 含石莼寡糖的石莼汁制品及其制备方法 | |
| CN104115995A (zh) | 一种提高动物精液活力的复合糖制剂及其应用 | |
| CN109068709B (zh) | 速溶产品及其制备方法 | |
| CN113813443A (zh) | 一种葡聚糖基水凝胶敷料及其制备方法 | |
| CN1561796A (zh) | 水溶性蜂皇浆及其干粉以及它们的制备方法 | |
| TW201626900A (zh) | 含有食物纖維之飲食品 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20220516 Address after: 276800 middle section of Huifeng Road, taoluo Town, Donggang District, Rizhao City, Shandong Province Patentee after: Juxin Jiuzhou (Shandong) Food Co.,Ltd. Address before: 266071 No. 23 East Hongkong Road, Laoshan District, Shandong, Qingdao Patentee before: QINGDAO HAIDA ZHONGCHUANG MARINE SCIENCE AND TECHNOLOGY Co.,Ltd. |